Printer Friendly

PERSEPTIVE BIOSYSTEMS ANNOUNCES APPOINTMENT OF DR. GEORGE R. LENZ AS VICE PRESIDENT OF RESEARCH AND DEVELOPMENT

 CAMBRIDGE, Mass., June 14 /PRNewswire/ -- PerSeptive Biosystems, Inc. (NASDAQ: PBIO) announced today that Dr. George R. Lenz has joined the company as vice president of research and development. Dr. Lenz comes to PerSeptive from The BOC Group's Corporate Technical Center, where he held the position of director, health care research and development. In that capacity, Dr. Lenz was responsible for initiating therapeutic projects in support of The BOC Group's health care business in critical care, pharmaceuticals, medical devices and disposables. Dr. Lenz created the computer-aided drug design function, began that company's biotechnology initiative and was responsible for development of novel biomaterials and biomedical sensor devices.
 Prior to his tenure at The BOC Group, Dr. Lenz was section head of central nervous system research at G.D. Searle & Company's research and development division, where he managed research programs in cognition, anxiety control and analgesia.
 Noubar B. Afeyan, Ph.D., PerSeptive's president and CEO, commented, "Dr. Lenz's broad experience in managing diverse life sciences research projects complements PerSeptive's integrated approach to unique technology development for clinical diagnostic and therapeutic drug screening formats."
 Dr. Lenz received his B.S. degree from the Illinois Institute of Technology, his M.S. and Ph.D. in chemistry from the University of Chicago, and Master's degree in management from Northwestern University. He has published over 60 articles, and holds 13 patents.
 PerSeptive Biosystems designs, manufactures and markets proprietary products and systems for the purification and analysis of biomolecules. These bioseparations products are designed to reduce significantly the time and cost required for the development and manufacture of biopharmaceuticals. The company's current and planned products for the purification and analysis of biomolecules are based on three interrelated core technologies: Perfusion Chromatography(R) for high resolution separations of biomolecules 10 to 1,000 times faster than conventional chromatography, ImmunoDetection(tm) for real-time immunoassays in a flow-through cartridge format and Rational Surface Design(tm) synthetic surfaces that bind biomolecules with the high specificity of antibodies.
 -0- 6/14/93
 /CONTACT: Robert A. Fein, senior vice president, finance, of PerSeptive Biosystems, Inc., 617-621-1787/
 (PBIO)


CO: PerSeptive Biosystems ST: Massachusetts IN: MTC SU: PER

SJ -- NE010 -- 1608 06/14/93 11:34 EST
COPYRIGHT 1993 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1993 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Jun 14, 1993
Words:361
Previous Article:VIEWSIM TO RECEIVE SIGN-OFF CERTIFICATION FROM LEADING ASIC VENDORS
Next Article:MIDLAND FUNDING CORP. I & II SENIOR DEBT LOWERED TO 'BB+/BB-' BY FITCH -- FITCH FINANCIAL WIRE --
Topics:


Related Articles
PERSEPTIVE BIOSYSTEMS ANNOUNCES THIRD QUARTER RESULTS
PERSEPTIVE BIOSYSTEMS, INC. INTRODUCES ID SENSOR CARTRIDGES
PERSEPTIVE BIOSYSTEMS NAMES HUBERT M. QUINN VICE PRESIDENT, CHEMICAL PRODUCTION
PERSEPTIVE BIOSYSTEMS, INC., ANNOUNCES SETTLEMENT OF DISPUTE WITH FORMER PRESIDENT
PERSEPTIVE BIOSYSTEMS INC., ANNOUNCES FORMATION OF PERSEPTIVE TECHNOLOGIES CORPORATION
PERSEPTIVE BIOSYSTEMS NAMES ALAIN MASSOT SENIOR VICE PRESIDENT, INTERNATIONAL
PERSEPTIVE BIOSYSTEMS ANNOUNCES ELECTION OF DR. WILLIAM POUNDS TO ITS BOARD OF DIRECTORS
PERSEPTIVE BIOSYSTEMS, INC. ANNOUNCES THIRD QUARTER RESULTS
PERSEPTIVE BIOSYSTEMS ANNOUNCES PROPOSED ACQUISITION OF VESTEC CORPORATION
PERSEPTIVE BIOSYSTEMS, INC. ANNOUNCES FIRST QUARTER FINANCIAL RESULTS; $0.05 EARNINGS PER SHARE BEFORE PTC-I BUYOUT

Terms of use | Copyright © 2016 Farlex, Inc. | Feedback | For webmasters